Filing Flows › Agenus (AGEN) › Guidance & outlook
Agenus (AGEN) guidance and outlook
Agenus' 10-Q filed Nov 5, 2026 makes 16 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 5, 2026
- On July 13, 2026, in connection with the Private Placement, the Company announced that it will conduct, and that the net proceeds of the Private Placement are expected to support, a strategic prioritization of BOT/BAL for the neoadjuvant treatment of
- Securities and Exchange Commission informed the Company that it has concluded its investigation as to the Company and does not intend to recommend an enforcement action against the Company.
- Our internal discovery and translational platforms support target identification, antibody generation, biomarker analysis and candidate selection, and have supported development of agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3 and TIGIT, all of which remain proprietary assets of Agenus.
- Interest expense, net increased to approximately $14.5 million for the three months ended September 30, 2026 from $13.2 million for the three months ended September 30, 2025, mainly due to increased non-cash interest recorded in connection with our Royalty Purchase Agreement with HCR, primarily attributable to increased sales forecasts of GSK’s vaccines containing our STIMULON QS-21 adjuvant and an increase of…
- Interest expense, net increased to approximately $44.4 million for the nine months ended September 30, 2026 from $39.3 million for the nine months ended September 30, 2025, mainly due to increased non-cash interest recorded in connection with our Royalty Purchase Agreement with HCR, primarily attributable to increased sales forecasts of GSK’s vaccines containing our STIMULON QS-21 adjuvant and an increase of the…
- Our product candidates are in various stages of development and significant additional expenditures will be required if we start new clinical trials, encounter delays in our programs, apply for regulatory approvals, continue development of our technologies, expand our operations, and/or bring our product candidates to market.
- We expect to incur significant losses over the next several years as we continue development of our technologies and product candidates, manage our regulatory processes, initiate and continue clinical trials, and prepare for potential commercialization of products.
- That balance excludes the $7.6 million held in escrow under the Zydus agreements, including $0.1 million of accrued interest, and does not include outstanding receivables under our early access programs, of which we have received $5.9 million during the third quarter of 2026 and we expect to receive the remaining balance, net of accrued rebates, of $11.8 million in future periods.
- Based on our current operating plan and projections, including scheduled debt payments in the look-forward period (the majority of which is secured by certain real estate properties), we believe our existing cash and cash equivalents, which include the net proceeds from the Private Placement, are expected to fund operations and capital expenditure requirements through the third quarter of 2027, assuming no…
- These projections reflect anticipated revenues from our early access programs and scheduled debt payments in the look-forward period.
- If all such warrants are exercised for cash, the Company expects these resources to fund operations through year-end 2031.
- We are actively pursuing additional financing and strategic alternatives, including corporate transactions, out-licensing arrangements, asset sales, project financing, additional debt or equity financings, and other strategic transactions, and we are in active discussions with potential strategic and financial partners regarding several of these alternatives.
Agenus' latest quarter
Agenus, Q3 2026: revenue $31.5M (+4% year over year), operating margin 36.2%, net earnings $1.5M, operating cash flow −$20.1M. The chart follows the revenue to costs, profit and cash.
Questions
What does Agenus expect?
On July 13, 2026, in connection with the Private Placement, the Company announced that it will conduct, and that the net proceeds of the Private Placement are expected to support, a strategic prioritization of BOT/BAL for the neoadjuvant treatment of Securities and Exchange Commission informed the Company that it has concluded its investigation as to the Company and does not intend to recommend an enforcement action against the Company. Our internal discovery and translational platforms support target identification, antibody generation, biomarker analysis and candidate selection, and have sup
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.